open access

Vol 27, No 5 (2020)
Review articles — Clinical cardiology
Published online: 2020-07-10
Get Citation

Feasibility of sacubitril/valsartan initiation early after acute decompensated heart failure

Agata Tymińska, Krzysztof Ozierański, Marcin Grabowski, Grzegorz Opolski, Paweł Balsam
DOI: 10.5603/CJ.a2020.0094
·
Pubmed: 32648251
·
Cardiol J 2020;27(5):625-632.

open access

Vol 27, No 5 (2020)
Review articles — Clinical cardiology
Published online: 2020-07-10

Abstract

Despite significant diagnostic and therapeutic advances, heart failure (HF) is linked with high mortality and morbidity. Hospitalization for decompensated HF is still the most common cause of hospitalization in adults. What is more, a particularly high risk of hospitalization (even up to 50% of patients) is observed within a few months after a previous HF hospitalization. Sacubitril/valsartan, a first-in-class drug, contains a neprilysin inhibitor (sacubitril) and an angiotensin II receptor blocker (valsartan). In PARADIGM-HF trial investigators showed, that sacubitril/valsartan significantly reduced primary endpoint combined with cardiovascular death or HF hospitalization in patients with chronic, symptomatic HF (New York Heart Association class II–IV) with reduced ejection fraction (left ventricular ejection fraction [LVEF] ≤ 35–40%). Recently, results of the PIONEER-HF trial, which included HF patients with LVEF ≤ 40% who were hospitalized for acute decompensated HF were also published. The study proved that early, in-hospital, implementation of sacubitril/valsartan in these patients resulted in a substantially greater reduction of N-terminal prohormone B-type natriuretic peptide concentration and a lower rate of HF rehospitalizations with similar safety profile for enalapril.

Abstract

Despite significant diagnostic and therapeutic advances, heart failure (HF) is linked with high mortality and morbidity. Hospitalization for decompensated HF is still the most common cause of hospitalization in adults. What is more, a particularly high risk of hospitalization (even up to 50% of patients) is observed within a few months after a previous HF hospitalization. Sacubitril/valsartan, a first-in-class drug, contains a neprilysin inhibitor (sacubitril) and an angiotensin II receptor blocker (valsartan). In PARADIGM-HF trial investigators showed, that sacubitril/valsartan significantly reduced primary endpoint combined with cardiovascular death or HF hospitalization in patients with chronic, symptomatic HF (New York Heart Association class II–IV) with reduced ejection fraction (left ventricular ejection fraction [LVEF] ≤ 35–40%). Recently, results of the PIONEER-HF trial, which included HF patients with LVEF ≤ 40% who were hospitalized for acute decompensated HF were also published. The study proved that early, in-hospital, implementation of sacubitril/valsartan in these patients resulted in a substantially greater reduction of N-terminal prohormone B-type natriuretic peptide concentration and a lower rate of HF rehospitalizations with similar safety profile for enalapril.

Get Citation

Keywords

sacubitril/valsartan, acute decompensated heart failure, angiotensin receptor neprilysin inhibitor, angiotensin receptor neprilysin inhibitors (ARNI)

About this article
Title

Feasibility of sacubitril/valsartan initiation early after acute decompensated heart failure

Journal

Cardiology Journal

Issue

Vol 27, No 5 (2020)

Pages

625-632

Published online

2020-07-10

DOI

10.5603/CJ.a2020.0094

Pubmed

32648251

Bibliographic record

Cardiol J 2020;27(5):625-632.

Keywords

sacubitril/valsartan
acute decompensated heart failure
angiotensin receptor neprilysin inhibitor
angiotensin receptor neprilysin inhibitors (ARNI)

Authors

Agata Tymińska
Krzysztof Ozierański
Marcin Grabowski
Grzegorz Opolski
Paweł Balsam

References (29)
  1. Savarese G, Lund LH. Global public health burden of heart failure. Card Fail Rev. 2017; 3(1): 7–11.
  2. Ponikowski P, Voors A, Anker S, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016; 37(27): 2129–2200.
  3. Ambrosy AP, Fonarow GC, Butler J, et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol. 2014; 63(12): 1123–1133.
  4. Balsam P, Ozierański K, Kapłon-Cieślicka A, et al. Differences in clinical characteristics and 1-year outcomes of hospitalized patients with heart failure in ESC-HF Pilot and ESC-HF-LT registries. Pol Arch Intern Med. 2019; 129(2): 106–116.
  5. Goldsmith SR. Interactions between the sympathetic nervous system and the RAAS in heart failure. Curr Heart Fail Rep. 2004; 1(2): 45–50.
  6. Fonarow GC, Stough WG, Abraham WT, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol. 2007; 50(8): 768–777.
  7. Kapłon-Cieślicka A, Tymińska A, Peller M, et al. Diagnosis, Clinical Course, and 1-Year Outcome in Patients Hospitalized for Heart Failure With Preserved Ejection Fraction (from the Polish Cohort of the European Society of Cardiology Heart Failure Long-Term Registry). Am J Cardiol. 2016; 118(4): 535–542.
  8. Solomon SD, Rizkala AR, Gong J, et al. Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rationale and design of the PARAGON-HF trial. JACC Heart Fail. 2017; 5(7): 471–482.
  9. Novartis. A randomized, double-blind controlled study comparing LCZ696 to medical therapy for comorbidities in HFpEF Patients (PARALLAX). http://clinicaltrials.gov/ct2/show/NCT03066804. NLM identifier: NCT03066804 (accessed 20 December 2017).
  10. Buggey J, Mentz RJ, DeVore AD, et al. Angiotensin receptor neprilysin inhibition in heart failure: mechanistic action and clinical impact. J Card Fail. 2015; 21(9): 741–750.
  11. Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2016; 68: 1476–1488.
  12. Braunwald E. The path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failure. J Am Coll Cardiol. 2015; 65(10): 1029–1041.
  13. Kaplinsky E. Sacubitril/valsartan in heart failure: latest evidence and place in therapy. Ther Adv Chronic Dis. 2016; 7(6): 278–290.
  14. von Lueder TG, Sangaralingham SJ, Wang BH, et al. Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure. Circ Heart Fail. 2013; 6(3): 594–605.
  15. McMurray J, Packer M, Desai A, et al. Angiotensin–Neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014; 371(11): 993–1004.
  16. Velazquez EJ, Morrow DA, DeVore AD, et al. PIONEER-HF Investigators. Angiotensin-Neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019; 380(6): 539–548.
  17. Kristensen SL, Jhund PS, Mogensen UM, et al. Prognostic value of N-terminal pro-B-type natriuretic peptide levels in heart failure patients with and without atrial fibrillation. Circ Heart Fail. 2017; 10(10).
  18. Nessler J, Straburzyńska-Migaj E, Windak A, et al. [Expert consensus on the usefulness of natriuretic peptides in heart failure.]. Kardiol Pol. 2018; 76(1): 215–224.
  19. Diez M, Talavera ML, Conde DG, et al. High-sensitivity troponin is associated with high risk clinical profile and outcome in acute heart failure. Cardiol J. 2016; 23(1): 78–83.
  20. Nakou ES, Marketou ME, Chlouverakis GI, et al. Troponin-I levels as a potential prognostic biomarker of sacubitril/valsartan treatment response in heart failure with reduced ejection fraction: Who will benefit most? Clin Cardiol. 2018; 41(12): 1548–1554.
  21. Desai AS, Claggett BL, Packer M, et al. PARADIGM-HF Investigators. Influence of Sacubitril/Valsartan (LCZ696) on 30-Day Readmission After Heart Failure Hospitalization. J Am Coll Cardiol. 2016; 68(3): 241–248.
  22. Novartis. Prospective ARNI vs. ACE inhibitor trial to determine superiority in reducing heart failure events after MI (PARADISE-MI). http://clinicaltrials.gov/ct2/show/NCT02924727. NLM identifier: NCT02924727 (accessed 29 December 2017).
  23. Pascual-Figal D, Wachter R, Senni M, et al. Rationale and design of TRANSITION: a randomized trial of pre-discharge vs. post-discharge initiation of sacubitril/valsartan. ESC Heart Fail. 2018; 5(2): 327–336.
  24. Wachter R, Senni M, Belohlavek J, et al. Sacubitril/Valsartan initiated in hospitalized patients with heart failure with reduced ejection fraction after hemodynamic stabilization: primary results of the TRANSITION study. J Cardiac Failure. 2018; 24(8): S15.
  25. Senni M, McMurray JJV, Wachter R, et al. Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens. Eur J Heart Fail. 2016; 18(9): 1193–1202.
  26. Luo N, Lippmann SJ, Mentz RJ, et al. Relationship between hospital characteristics and early adoption of angiotensin-receptor/neprilysin inhibitor among eligible patients hospitalized for heart failure. J Am Heart Assoc. 2019; 8(3): e010484.
  27. Seferovic PM, Ponikowski P, Anker SD, et al. Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019; 21(10): 1169–1186.
  28. Balsam P, Peller M, Borodzicz S, et al. In-hospital heart rate reduction and its relation to outcomes of heart failure patients with sinus rhythm: Results from the Polish part of the European Society of Cardiology Heart Failure Pilot and Long-Term Registries. Cardiol J. 2020; 27(1): 25–37.
  29. Cowie MR, Anker SD, Cleland JGF, et al. Improving care for patients with acute heart failure: before, during and after hospitalization. ESC Heart Fail. 2014; 1(2): 110–145.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl